Captrust Financial Advisors Apellis Pharmaceuticals, Inc. Transaction History
Captrust Financial Advisors
- $43.1 Billion
- Q2 2025
A detailed history of Captrust Financial Advisors transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Captrust Financial Advisors holds 29,532 shares of APLS stock, worth $634,052. This represents 0.0% of its overall portfolio holdings.
Number of Shares
29,532
Previous 29,280
0.86%
Holding current value
$634,052
Previous $640,000
20.16%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding APLS
# of Institutions
302Shares Held
134MCall Options Held
2.97MPut Options Held
623K-
Avoro Capital Advisors LLC New York, NY12.2MShares$262 Million3.86% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$255 Million17.74% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.2MShares$218 Million0.0% of portfolio
-
Morgan Stanley New York, NY9.75MShares$209 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA8.98MShares$193 Million0.03% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $2.36B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...